RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC20H25ClN6O2S

InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N

CAS Registry1423719-30-5

Clinical Trials associated with Nerandomilast

JPRN-jRCT2030260406

/ Not yet recruitingPhase 3

A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

Start Date01 Sep 2026

Sponsor / Collaborator

Nippon Boehringer Ingelheim Co., Ltd.

NCT07540988

/ Not yet recruitingPhase 3

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression.
Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date28 Aug 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07497087

/ RecruitingPhase 3

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Oral Nerandomilast Treatment in Patients With Systemic Sclerosis (SSc)

Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day.
Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date27 Jul 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Nerandomilast

100 Translational Medicine associated with Nerandomilast

100 Patents (Medical) associated with Nerandomilast

Literatures (Medical) associated with Nerandomilast

01 Jul 2026·EUROPEAN RESPIRATORY JOURNAL

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial

Article

Author: Richeldi, Luca ; Gu, Hui ; Hoffmann-Vold, Anna-Maria ; Valenzuela, Claudia ; Maher, Toby M ; Oldham, Justin M ; Stowasser, Susanne ; Assassi, Shervin ; Martinez, Fernando J ; Ritter, Ivana ; Wijsenbeek, Marlies S ; Azuma, Arata ; Kreuter, Michael ; Cottin, Vincent

Background:

In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg twice daily and 18 mg twice daily (hereafter nerandomilast 9 mg and 18 mg, respectively) reduced the decline in forced vital capacity at week 52 compared with placebo (primary end-point). We assessed the effects of nerandomilast up to the final database lock.

Methods:

Time to first acute exacerbation of interstitial lung disease, hospitalisation for respiratory cause or death (key secondary end-point) and other time-to-event end-points were assessed.

Results:

1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At the final database lock, the mean± sd exposure to trial medication was 15.1±5.7 months and the mean± sd observation period was 17.0±4.1 months. Compared with placebo, the hazard ratio for the key secondary end-point was 0.78 (95% CI 0.61–1.00) for nerandomilast 9 mg and 0.77 (95% CI 0.60–0.99) for nerandomilast 18 mg; hazard ratios were lower among patients not taking nintedanib (0.69 (95% CI 0.49–0.97) and 0.65 (95% CI 0.46–0.92), respectively) than among those taking background nintedanib (0.90 (95% CI 0.63–1.30) and 0.93 (95% CI 0.65–1.34), respectively). For death, the hazard ratio versus placebo was 0.51 (95% CI 0.34–0.78) for both nerandomilast doses. Adverse events led to discontinuation of trial medication in 12.5%, 12.0% and 12.3% of the placebo, nerandomilast 9 mg and nerandomilast 18 mg groups, respectively.

Conclusions:

In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.

01 Jun 2026·BMJ medicine

Pulmonary fibrosis: evolving therapeutic pipeline

Review

Author: Rooney, Rebecca ; Shannon, Laura ; Hilary, Benjamin ; Murphy, Gary ; Chaudhuri, Nazia ; Islam, Sabria ; Bailey, Simon

Current treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the disease. These treatments are widely used globally. Emerging agents, such as nerandomilast, showed positive results in phase 3 trials and was approved in the US in 2025 for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, but is not yet licensed for clinical use in the UK. As our understanding of the pathogenesis of pulmonary fibrosis advances, so does the potential to develop treatments that more effectively target underlying mechanisms while being safe and well tolerated. Insights into key pathogenic pathways, including epithelial injury, fibroblast activation, extracellular matrix deposition, B and T cell involvement, and dysregulated cytokine signalling pathways, have enabled various therapeutic targets to be explored. Despite the extensive efforts behind each study, many questions remain unanswered. Negative trials are equally important, in providing insights into how future clinical trials can be better designed and targeted. Meanwhile, positive studies show encouraging results and identify potential treatments, all contributing to the overarching goal of not just slowing, but ultimately reversing, fibrosis.

01 May 2026·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Will the anti-fibrotic effects of nerandomi-last? FIBRONEER-IPF part 2

Article

Author: Khor, Yet H ; Jenkins, R Gisli

108

News (Medical) associated with Nerandomilast

30 Jul 2026

·www.globenewswire.com

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory effectsPhase III FIBRONEER™️trials demonstrated that nerandomilast effectively slows lung function decline in adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF), two life-threatening, progressive lung conditions1,2,3,4Nerandomilast demonstrated a favorable safety and tolerability profile in clinical trials, notably, with monotherapy discontinuation rates similar to placebo Ingelheim, Germany - Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorization for JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This marks the first new treatment approved in IPF in the EU in over a decade and for PPF in more than five years. As a first-in-class oral preferential phosphodiesterase 4B (PDE4B) inhibitor, nerandomilast addresses a critical unmet need by successfully slowing disease progression while remaining tolerable. “With JASCAYD®, physicians across the EU gain a long-awaited, new treatment option for people living with IPF and PPF that is effective, has a well-characterized safety profile and may support long-term adherence,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “This milestone is a major advancement, but it must also be a catalyst for broader recognition that lungs can’t wait. Earlier recognition and diagnosis of pulmonary fibrosis are crucial because for people living with a progressive disease, every moment matters.” The EC approval follows the positive CHMP opinion received in May and is based on results from the FIBRONEER™ Phase III program, the largest clinical trial program conducted in IPF and PPF to date.1,2 In both the FIBRONEER™-IPF and FIBRONEER™-ILD trials, the primary endpoint was met: nerandomilast successfully slowed lung function decline, measured by absolute change in forced vital capacity (FVC)* from baseline to week 52 compared to placebo.1,2 While the key secondary endpoint was not met in either trial,** a numerical reduction in mortality was observed across both trials, reaching nominal significance in FIBRONEER™-ILD.1,2 Nerandomilast demonstrated a favorable safety and tolerability profile with no requirement for liver monitoring. As monotherapy, it showed similar discontinuation rates to placebo.1,2 “One of the challenges of managing IPF and PPF is seeing patients needing to stop treatment early because the side effects are too much to tolerate,” said Prof Marlies Wijsenbeek, Pulmonary Physician at the Erasmus MC University Medical Centre. “The FIBRONEER™ trials showed us that nerandomilast preserves lung function with a tolerability profile that allows patients to stay on their medication, which is a major clinical advancement that patients across the EU have been waiting for. Also, removing the burden of ongoing liver monitoring is an additional improvement for patients.” IPF and PPF affect more than 500,000 people across Europe,5 causing irreversible lung scarring that severely restricts breathing. Despite the life-threatening nature of these conditions, where approximately half of those diagnosed lose their lives within five years6,7,8 – a prognosis worse than many cancers.7,9,10 – many people delay or stop existing therapies due to side effects such as nausea, photosensitivity, and diarrhea.11,12,13 In IPF specifically, approximately half of those who stop therapy do so within six months.13 “When diagnosed with a progressive and irreversible lung condition like IPF or PPF, your greatest fear is running out of treatment options,” said Sue Farrington, President of the Federation of European Scleroderma Associations (FESCA). “Today’s authorization is a long-awaited breakthrough for the IPF and PPF community in the EU and offers renewed hope for people living with systemic sclerosis and other diseases that can lead to progressive lung fibrosis. Having a therapy that patients can reliably stay on to preserve their lung health brings real stability and hope to families.” About IPF and PPF Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are both conditions characterized by irreversible build-up of scar tissue in the lungs, affecting the lungs’ ability to take in and transfer oxygen into the bloodstream.14,15,16 Once lung function is lost, it’s lost forever. Signs and symptoms of IPF and PPF include a persistent dry cough, shortness of breath, fatigue and finger/toe clubbing (widening and rounding of the tips of fingers/toes).4,16 In IPF, the root cause of pulmonary fibrosis is not known.14 The disease primarily affects people over the age of 50 and affects more men than women.17 In PPF, the scarring of the lungs may be linked to an existing condition (e.g. rheumatoid arthritis or systemic sclerosis), result from exposure to inhaled substances (e.g. asbestos or mold), or be due to an unknown cause (idiopathic) and worsens despite treatment of the condition.15 Together, IPF and PPF may affect up to 9.2 million people worldwide.5,18 Approximately half of people with IPF or PPF die within 5 years of diagnosis6,7,8 – a higher mortality than many cancers.7,9,10 About nerandomilast JASCAYD® (nerandomilast) is a twice daily oral, preferential PDE4B inhibitor with antifibrotic and immunomodulatory effects approved in the United States, China, the United Arab Emirates, Japan, Thailand, the United Kingdom, Brazil and the European Union for the treatment of adults with IPF and for the treatment of adults with PPF. Regulatory submissions for nerandomilast in IPF and PPF are also under review in other countries with additional approvals anticipated in 2026. Boehringer Ingelheim is also exploring the potential of nerandomilast in two rheumatic diseases: systemic sclerosis (SSc) and myositis (IIM). Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. References *FVC is a measure of lung function, measured in mL. **The key secondary endpoint was time to first acute IPF/ILD exacerbation, first hospitalization for respiratory cause, or death over the duration of trial Richeldi, et al. NEJM. 2025;392:2193-2202.Maher, et al. NEJM. 2025. doi:10.1056/NEJMoa2503643Hoyer N, et al. Respir Res. 2019;20(1).Grant-Orser A, et al. BMJ Open Respir Res. 2024;11:e002333.Cottin V, et al. Front Med (Lausanne). 2022;9:799912.Zheng Q et al. ERJ Open Res. 2022;8(1):00591-2021.Cen Z, et al. Ann Med. 2024;56(1):2406439.Nasser M, et al. Respir Res 2021;22:162.Siegel RL, et al. A Cancer Journal for Clinicians. 2024;74(1):12–49.Vancheri C, et al. Eur Respir J. 2010;35(3):496–504.Esbriet SmPC — Roche, 2014.Ofev SmPC — Boehringer Ingelheim, 2025 (Last updated: Oct 2025).Levra S et al. Biomedicines. 2022;10(12):3229.Upagupta C, et al. Eur Respir Rev. 2018;27:180033.Kondoh Y, Inoue Y. Adv Ther. 2025;42(7):2988–3001.van Cleemput, J, et al. Adv Ther. 2019;36, 298–317.Wang J, et al. MedComm (2020). 2024;5(10):e744.Podolanczuk A, et al. Eur Respir J. 2023;61(4). Attachment Boehringer headquarters

Clinical ResultDrug ApprovalPhase 3

15 Jul 2026

·pmlive.com

Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Jascayd is the first treatment of its kind licensed for use in IPF and PPF in adults. The MHRA authorisation is based on the results of the pivotal phase 3 clinical trials involving 1,177 and 1,176 patients with IPF and PPF respectively. Currently, there is a high unmet need for patients, as there are few treatment options that slow the disease progression, with IPF being described as having a five-year survival rate of just 45.6%, comparable with many cancers. Over 5,000 people in the UK die each year from IPF, which represents around 1 in 100 deaths nationwide. “The MHRA authorisation of nerandomilast is a meaningful advancement in the management of this condition, where there is high mortality and a substantial impact on quality of life,” commented Douglas Clark, Medical Director of Boehringer Ingelheim UK & Ireland. “We are now working closely with NICE, aiming to bring nerandomilast to eligible patients on the NHS as soon as possible.” Pulmonary fibrosis is a chronic and ultimately fatal condition characterised by irreversible lung scarring and a continuous decline in lung function. Symptoms include worsening breathlessness, a persistent dry cough and fatigue. Antifibrotics have been the mainstay of treatment for the past decade, with no effective treatment innovations licensed since then. “A diagnosis of progressive pulmonary fibrosis means that life expectancy is reduced while day-to-day quality of life can often deteriorate, as breathlessness and fatigue worsen,” commented Professor Philip Molyneaux, Consultant Respiratory Physician and Professor of Interstitial Lung Disease at Imperial College London. “With the authorisation of nerandomilast by the MHRA, clinicians have a new treatment option that can slow the decline in lung function, expanding the choices available for eligible patients.” NICE is evaluating Jascayd to treat adults with IPF or PPF, with guidance expected in September 2026. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical Result

15 Jul 2026

·firstwordpharma.com

Biopharma bites: Boehringer's 2Q, another deal for Chai, and more from Keytruda, Wegovy

Boehringer's Hernexeos faces long road to EuropeChai extends pharma deal streak with argenxKeytruda may offer chemo-free option in endometrial cancerNovo cracks open Europe's oral GLP-1 market Boehringer's Hernexeos faces long road to EuropeBoehringer Ingelheim said its newly launched lung cancer drug Hernexeos (zongertinib) is not expected to reach patients in Europe until 2028.The oral therapy for HER2-mutant advanced non–small-cell lung cancer has already launched in the US — where it obtained a full approval by the FDA earlier this year after an accelerated approval last August — as well as in China and Japan, but the company said it will wait for Phase III data before seeking a European launch.The delayed European rollout was disclosed during Boehringer's first-half results presentation, where it reported a 16.2% currency-adjusted increase in sales to €15.8 billion, driven by diabetes, heart failure and chronic kidney disease medicine Jardiance (empagliflozin). The drug generated €5.7 billion, benefiting from a "large and growing patient base" and higher volumes following changes to the US pricing and reimbursement environment.Boehringer also highlighted strong early demand for Jascayd (nerandomilast), its treatment for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which has been approved in the US, China, Japan and several other markets while awaiting an EU decision. The company said recent launches, together with Jardiance, helped lift Human Pharma sales 20.1% to €13.1 billion in the first half.Chai extends pharma deal streak with argenxOn the heels of a $400-million series C that more than doubled its valuation, Chai Discovery has again added to its list of pharma collaborators by striking an AI-driven antibody discovery pact with argenx.Under the deal, argenx gains early access to Chai's molecular design platform to support de novo antibody discovery against therapeutic targets, adding another major partner alongside recent collaborations with Novartis, Pfizer and Eli Lilly.The partnership combines argenx's antibody engineering and immunology expertise with Chai's generative AI models, which are designed to predict and reprogramme molecular interactions to create biomolecules with specific functional properties.Keytruda may offer chemo-free option in endometrial cancerMerck & Co. said Keytruda (pembrolizumab) significantly improved progression-free survival (PFS) over standard platinum-doublet chemotherapy in a Phase III trial of patients with mismatch repair deficient advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence more than six months after completing prior adjuvant therapy. Findings from the KEYNOTE-C93 study could pave the way for a potential chemo-free treatment option in the frontline setting, indicated Brian Slomovitz, the trial's overall principal investigator. According to Merck, KEYNOTE-C93 is also the first Phase III trial to show a PD-1 inhibitor used alone can outperform platinum doublet chemotherapy in this patient population.At an interim analysis, the study met its PFS endpoint, while showing a "trend toward improvement" on the other main goal of overall survival, though those data are still immature. Keytruda also demonstrated clinically meaningful overall and complete response rates, along with durable responses, Merck said. Results from the ongoing trial are set to be presented at an upcoming medical meeting and submitted to regulators.Novo cracks open Europe's oral GLP-1 marketNovo Nordisk has added two more arrows to its obesity-treatment quiver after obtaining approval from the European Commission for its Wegovy pill, making it the EU's first oral GLP-1 therapy for chronic weight management, alongside a higher-dose 7.2-mg Wegovy injection in a single ready-to-use pen.The Wegovy pill, which was granted a positive opinion from the EU's drug advisory body in May, was approved based on study data showing that people who took it lost an average 17% of their body weight after 64 weeks on treatment, ‌compared ⁠with about 3% with placebo. Meanwhile, Novo said the new 7.2-mg injector has demonstrated average weight loss of 21% in clinical studies.The oral product has now secured approvals in five markets, following earlier green lights in the US, UK, United Arab Emirates and Bahrain. Wednesday's nod gives the Wegovy pill a headstart in the EU market over Eli Lilly's competing product Foundayo (orforglipron), which has yet to clear regulators there.

Clinical ResultDrug ApprovalPhase 3Accelerated Approval

100 Deals associated with Nerandomilast

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive fibrotic interstitial lung disease	European Union	Boehringer Ingelheim GmbH	15 Jul 2026
Progressive fibrotic interstitial lung disease	Iceland	Boehringer Ingelheim GmbH	15 Jul 2026
Progressive fibrotic interstitial lung disease	Liechtenstein	Boehringer Ingelheim GmbH	15 Jul 2026
Progressive fibrotic interstitial lung disease	Norway	Boehringer Ingelheim GmbH	15 Jul 2026
Progressive pulmonary fibrosis	China	Boehringer Ingelheim International GmbH	09 Dec 2025
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	07 Oct 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CREST Syndrome	Phase 3	United States	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	China	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Japan	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Argentina	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Australia	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Austria	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Belgium	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Brazil	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Bulgaria	Boehringer Ingelheim GmbH	27 Jul 2026
CREST Syndrome	Phase 3	Canada	Boehringer Ingelheim GmbH	27 Jul 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06195072 (CONQUEST, EULAR2026)	Phase 2	Interstitial lung disease due to systemic disease	127	Amlitelimab	rzphqtlrmr(vzgzjqeuqi) = muletyzwfu apoahgencx (hjuskydcsk ) View more	Positive	11 Jun 2026
NCT05321082 (FIBRONEER-ILD, CTgov)	Phase 3	Progressive fibrotic interstitial lung disease	1,178	Placebo (Placebo)	tzulzryhxa(vubespvmsp) = crftypxdue yotngogcqy (gqzmnxivbk, vnoyhhhstj - ujoqudzndi) View more	-	09 Jan 2026
				BI 1015550 (Nerandomilast 9 mg)	tzulzryhxa(vubespvmsp) = vdqmwqyybg yotngogcqy (gqzmnxivbk, urllajmpjo - aqqiiowpje) View more
NCT06624072 (CTgov)	Phase 1	-	15	Nerandomilast (Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1))	fctcaauvai(vvrbmzkqyt) = xmlppbsbpp ujuuodygqg (xxzubkpclh, NA) View more	-	08 Jan 2026
				Nerandomilast (Nerandomilast 18 mg Adult Fasted State (Reference R))	fctcaauvai(vvrbmzkqyt) = qxbqkhfadn ujuuodygqg (xxzubkpclh, NA) View more
NCT06070610 (CTgov)	Phase 1	-	14	Pirfenidone+Nintedanib (Pirfenidone/Nintedanib alone (Reference))	qcduekgqhk(pluddpoboo) = fgtlgbavad hexlgkwrfd (uixkomrdmo, NA) View more	-	02 Dec 2025
				Pirfenidone+Nerandomilast+Nintedanib (Pirfenidone/Nintedanib in combination with Nerandomilast (Test))	qcduekgqhk(pluddpoboo) = csoummdasw hexlgkwrfd (uixkomrdmo, NA) View more
NCT06408870 (CTgov)	Phase 1	-	64	BI 1015550 (BI 1015550 Formulation C1 (Reference, R))	lukynurzgr(gjwspxgptx) = ldkasyifld khwyxnbxqf (kiyjoknzlp, na) View more	-	01 Dec 2025
				BI 1015550 (BI 1015550 Formulation C2 (Test, T))	lukynurzgr(gjwspxgptx) = knujitasmd khwyxnbxqf (kiyjoknzlp, na) View more
NCT05550636 (CTgov)	Phase 1	-	15	Midazolam (Midazolam (R))	urdbxgsmyv(ozskaxkwlu) = acrhhujsry sbhzzokkmi (ryralkcret, NA) View more	-	01 Dec 2025
				Midazolam (T+BI 1015550 (BI 1015550 + Midazolam (T))	urdbxgsmyv(ozskaxkwlu) = grjbtzalkm sbhzzokkmi (ryralkcret, NA) View more
NCT06415045 (CTgov)	Phase 1	-	18	Nerandomilast (Nerandomilast fasted state (Reference (R)))	yarqklaqsb(hxrfumdhhg) = hylnwpadjb frrhqvalnq (iipmwhweuc, NA) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast fed state (Test (T)))	yarqklaqsb(hxrfumdhhg) = wrlqryjguw frrhqvalnq (iipmwhweuc, NA) View more
NCT06139302 (CTgov)	Phase 1	-	12	Nerandomilast (Nerandomilast 9 mg)	tjpqjumlcq(agfwyayhns) = zdgqmmuncs tycgurrvqo (czuhspblea, 13.8) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast 18 mg)	tjpqjumlcq(agfwyayhns) = ygrzjwitgz tycgurrvqo (czuhspblea, 52.8) View more
NCT06393127 (CTgov)	Phase 1	-	64	nerandomilast (Test treatment (T))	tjwsgpbltq(niawdntrcv) = qsovceucij shgdhquufk (fydnsicbfs, NA) View more	-	01 Dec 2025
				nerandomilast (Reference treatment (R))	tjwsgpbltq(niawdntrcv) = eiuyerjbwf shgdhquufk (fydnsicbfs, NA) View more
NCT05707403 (CTgov)	Phase 1	-	8	R-BI 1015550 (R-BI 1015550 18 mg tablet (T))	zrdkitzaqy(euqqdakbam) = bmcrvvbrhg xrqwvuevyo (daeapyrtyi, 1.07) View more	-	28 Nov 2025
				14C-R-BI 1015550 (14C-R-BI 1015550 10 μg i.v. (R))	zrdkitzaqy(euqqdakbam) = gilqrrmwsa xrqwvuevyo (daeapyrtyi, 1.07) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis